Nautilus Biotechnology, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Nautilus Biotechnology, Inc. (NAUT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-28
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.16M, a 32.01% decline year-over-year.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.37M, a 36.90% decline year-over-year.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.47M, a 52.91% decline year-over-year.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.50M, a 53.02% decline year-over-year.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.84M, a 46.11% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $12.70M, a 4.65% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $12.14M, a 16.93% increase from fiscal 2022.
- Nautilus Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.38M, a 30.83% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.16M 10-Q · filed 2026-07-28 | $2.53M 10-Q · filed 2026-07-28 | $4.00M derived: sum of 3 quarters · filed 2026-07-28 | $5.50M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $1.37M 10-Q · filed 2026-04-28 | $2.84M derived: sum of 2 quarters · filed 2026-04-28 | $4.33M derived: sum of 3 quarters · filed 2026-04-28 | $6.04M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.97M derived: sum of 2 quarters · filed 2026-02-26 | $4.68M derived: sum of 3 quarters · filed 2026-07-28 | $6.84M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.50M 10-Q · filed 2025-10-28 | $3.21M derived: sum of 2 quarters · filed 2026-07-28 | $5.37M 10-Q · filed 2025-10-28 | $8.50M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $1.71M 10-Q · filed 2026-07-28 | $3.88M 10-Q · filed 2026-07-28 | $7.00M derived: sum of 3 quarters · filed 2026-07-28 | $10.19M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $2.17M 10-Q · filed 2026-04-28 | $5.29M derived: sum of 2 quarters · filed 2026-04-28 | $8.48M derived: sum of 3 quarters · filed 2026-04-28 | $11.76M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.31M derived: sum of 2 quarters · filed 2026-02-26 | $9.59M derived: sum of 3 quarters · filed 2026-02-26 | $12.70M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.18M 10-Q · filed 2025-10-28 | $6.46M derived: sum of 2 quarters · filed 2025-10-28 | $9.58M 10-Q · filed 2025-10-28 | $12.65M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | $3.28M 10-Q · filed 2025-07-31 | $6.39M 10-Q · filed 2025-07-31 | $9.47M derived: sum of 3 quarters · filed 2025-07-31 | $12.57M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $3.11M 10-Q · filed 2025-04-29 | $6.19M derived: sum of 2 quarters · filed 2025-04-29 | $9.29M derived: sum of 3 quarters · filed 2025-04-29 | $12.39M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.18M derived: sum of 2 quarters · filed 2025-02-27 | $9.28M derived: sum of 3 quarters · filed 2025-02-27 | $12.14M 10-K · filed 2025-02-27 |
| 2023-09-30 | $3.11M 10-Q · filed 2024-10-29 | $6.20M derived: sum of 2 quarters · filed 2024-10-29 | $9.06M 10-Q · filed 2024-10-29 | $11.90M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $3.10M 10-Q · filed 2024-07-30 | $5.96M 10-Q · filed 2024-07-30 | $8.79M derived: sum of 3 quarters · filed 2024-07-30 | $11.66M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $2.86M 10-Q · filed 2024-04-30 | $5.69M derived: sum of 2 quarters · filed 2024-04-30 | $8.56M derived: sum of 3 quarters · filed 2024-04-30 | $11.13M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $5.70M derived: sum of 2 quarters · filed 2024-02-28 | $8.27M derived: sum of 3 quarters · filed 2024-02-28 | $10.38M 10-K · filed 2024-02-28 |
| 2022-09-30 | $2.87M 10-Q · filed 2023-10-31 | $5.44M derived: sum of 2 quarters · filed 2023-10-31 | $7.55M 10-Q · filed 2023-10-31 | $10.08M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | $2.57M 10-Q · filed 2023-08-02 | $4.68M 10-Q · filed 2023-08-02 | $7.21M derived: sum of 3 quarters · filed 2023-08-02 | $9.46M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $2.11M 10-Q · filed 2023-05-02 | $4.64M derived: sum of 2 quarters · filed 2023-05-02 | $6.89M derived: sum of 3 quarters · filed 2023-05-02 | $8.71M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.78M derived: sum of 2 quarters · filed 2023-02-23 | $6.60M derived: sum of 3 quarters · filed 2023-02-23 | $7.93M 10-K · filed 2023-02-23 |
| 2021-09-30 | $2.25M 10-Q · filed 2022-11-01 | $4.07M derived: sum of 2 quarters · filed 2022-11-01 | $5.40M 10-Q · filed 2022-11-01 | $5.65M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $1.82M 10-Q · filed 2022-08-02 | $3.16M 10-Q · filed 2022-08-02 | $3.41M derived: sum of 3 quarters · filed 2022-08-02 | $3.46M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $1.34M 10-Q · filed 2022-05-03 | $1.59M derived: sum of 2 quarters · filed 2022-05-03 | $1.65M derived: sum of 3 quarters · filed 2022-05-03 | $1.69M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $309.00K derived: sum of 2 quarters · filed 2022-02-24 | $350.00K derived: sum of 3 quarters · filed 2022-02-24 | $369.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $59.00K 10-Q · filed 2021-11-02 | $100.00K derived: sum of 2 quarters · filed 2021-11-02 | $119.00K 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $41.00K 10-Q · filed 2021-08-10 | $60.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |